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Testicular Germ Cell Tumor (TGCT) is the most common 
malignant tumor in young Caucasian men with an annual 
increase of 3–6% in the past 50 years. Data in the literature 
indicate that both environmental and genetic factors acting on 
the primordial gonocyte/gonocyte are implicated in the etio-
pathogenesis of this tumour. Genetic linkage and genome-wide 
analyses did not reveal a major gene effect so far, implying that 
multiple loci must contribute to the development of TGCTs. 
Only one significant genetic risk factor has been reported, the so 
called “gr/gr” deletion of the Y chromosome which still request 
further confirmation by independent studies. On the other side, 
the analysis of somatic genetic changes through mutation and 
genome imbalance analyses and expression profiling has just 
began to unravel the complex interaction of multiple pathways 
involved in TGCTs. This review focuses on genetic factors (both 
genomic and somatic) involved in the etiology, progression and 
treatment sensitivity of TGCTs.
Introduction
Testicular Germ Cell Tumor (TGCT) is the most common 
malignant tumor—accounting for up to 60% of all malignancies—
in young Caucasian men aged between 20 and 40 years.1,2 Clinically 
and histologically they are divided into seminomas and nonsemi-
nomas. The worldwide incidence of TGCTs is between 6–11 per 
100,000, with significant variation. It has more than doubled in the 
past 50 years with an annual increase of 3–6%.3,4 Epidemiological 
associations suggest that TGCTs are associated with other reproduc-
tive disorders, including hypospadias, cryptorchidism and impaired 
sperm production. Therefore, these conditions may share, in part, 
a common aetiology and this has given rise to the term “testic-
ular dysgenesis syndrome”.5 The TDS hypothesis proposes that 
abnormal gonadal development (dysgenesis) along the male lineage, 
which can have numerous primary causes, leads secondarily to 
disturbed Sertoli—and Leydig cell function, resulting in reproduc-
tive disorders.
Concerning TGCTs, there is accumulating evidence of an intra-
uterine phase of initiation that may involve both environmental 
and genetic factors acting on the primordial gonocyte/gonocyte.1,6-8 
This is the most likely reason that markers for embryonic germ cells, 
like OCT3/4 (see below), are diagnostic for the precursor lesion of 
TGCTs. Epidemiological studies showing striking geographical and 
ethnic differences largely support the TDS hypothesis.9 Observations 
on populations migrating from countries with high incidence 
(Denmark) and with markedly lower incidence (Finland) to Sweden 
provided evidence for the importance of environmental factors acting 
at prenatal/perinatal period. The first generation immigrants retained 
the incidence as in their country of origin, whereas the second gener-
ation (born in Sweden) had a similar risk to native Swedes.10 The 
most likely environmental chemicals acting in utero able to provoke 
TDS seem to be endocrine disruptors (xeno-estrogens), although 
direct evidence is lacking so far.11
Concerning ethnic differences, it is well known that Asian and 
African populations have a low risk of TGCTs and in contrast to 
what was observed in the Scandinavian migrating populations, men 
with African or Asian descent maintains their low risk even inhabiting 
in an area of high risk. This has been observed in African-Americans 
living in the USA for many generations12 indicating the importance 
of inherited susceptibility factors as well. In fact, it demonstrates the 
dominance of genetics over environment in these cases. This review 
focuses on genetic factors involved in the aethiology, progression and 
treatment sensitivity of TGCTs.
Inherited Susceptibility Factors
TGCTs can occur in a sporadic or familial manner (about 2%). 
Family history is among the strongest risk factors for TGCTs with 
a relative risk to a brother of a TGCT case of 8–10 and between 
fathers and sons of 4–6.10,13-16 These figures are much higher than 
those reported for most other cancer types, which rarely exceed 4.17 
Other evidences for strong hereditary component come from twin 
studies showing a greater concordance for disease in monozygotic 
than in dizygotic twins18,19 and from segregation analysis of familial 
cases suggesting a recessive mode of inheritance.20 The link between 
bilateral TGCTs and genetic factors has been further strengthen by 
demonstrating that brothers and fathers of bilateral cases have 4,7 fold 
and 3,9 fold greater risk to develop a TGCT than those of monolateral 
cases.21 These data clearly indicate that susceptibility genes do play a 
role in the aethiology of TGCTs and bilateral and familial cases are the 
most obvious candidates for searching inherited susceptibility factors.
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Genetic Linkage Analysis
Thanks to genetic linkage anal-
ysis a number of cancer susceptibility 
alleles have been identified. Concerning 
TGCTs a major effort was made by the 
International Testicular Cancer Linkage 
Consortium (ITCLC) in collecting 
a sufficiently large set of multiple-case 
families for genetic linkage studies.20 The 
first set of pedigrees (n = 134) provided 
strong evidence of a susceptibility locus at 
Xq27 in a subset of families with disease 
distribution compatible with X linkage 
(HLOD = 2.01) and history of at least 
one bilateral case (HLOD = 4.7).22 The 
high Heterogeneity LOD score (HLOD) 
was not confirmed when subsequently 
163 additional pedigrees were studied. 
Although a relevant gene in this region 
cannot be excluded, if it exists it would 
account only for a small proportion of 
TGCT susceptibility, possibly related to 
cryptorchidism.20
The same Consortium published the 
results of a genome-wide analysis on 237 
TGCT pedigrees indicating six “regions 
of interest” at different autosomal chro-
mosomes.23 However, simulation analysis 
suggested that neither of these loci is likely 
to explain a sibling relative risk of 4.20 It 
is therefore clear that susceptibility to 
TGCTs cannot be due to one major gene 
effect and multiple loci must contribute.
The Precursor Lesion of TGCTs
The most likely precursor of TGCT is a gonocyte or primordial 
germ cell that escaped normal maturation. This lesion is known as 
carcinoma in situ (CIS)7 or the Intratubular Germ Cell Neoplasia 
Unclassified (ITGCNU) according to the World health Organization 
(WHO)24 The counterpart of CIS in the dysgenetic gonad (see 
below) is known as gonadoblastomas. These precursors can progress 
to invasive components of different histologies, including seminoma 
as well as various types of nonseminomas (i.e., embryonal carci-
noma, teratoma, yolk sac tumor and choriocarcinoma). OCT3/4 
is diagnostic to identify CIS, gonadoblastoma, seminoma and 
embryonal carcinoma.25,26 In line with this origin of TGCTs, indi-
viduals with severe abnormalities of gonadal development associated 
with the intersex syndrome, currently referred to as Disorders of 
Sex Development (DSD)27 show an increased risk for this kind of 
cancer, in which the Y chromosome genetic material is of crucial 
importance.8,28
The Y Chromosome
The commonest structural abnormalities of the Y chromosome 
are microdeletions of the long arm of the Y chromosome (Yq). The 
Yq contain three AZF (AZoospermia Factor) regions, AZFa, b and 
c in which are mapping genes that are most likely to be involved in 
germ cell differentiation and spermatogenesis (Fig. 1).29,30 The dele-
tion of one or more AZF regions is strictly associated with impaired 
sperm production31 and also distinct Y chromosome lineages (Y 
haplogroups) have been reported as predisposing factors for oligo/
azoospermia.32,33 Recently, a novel deletion designated “gr/gr”, 
which removes half of the gene content of the AZFc region, has been 
identified.34 Although its clinical significance has been questioned, 
if only studies in which all potential methodological and selection 
biases were avoided are considered, “gr/gr” deletion is a significant 
risk factor for impaired spermatogenesis.35
While the role of Y chromosome is clearly established in male 
infertility, the search for Y related genetic risk factor(s) for TGCT 
has been largely unsuccessful. The logic behind the analysis of Y 
chromosome lineages in affected (cancer) versus unaffected controls 
is based on the assumption that an increased (or decreased) frequency 
of a particular Y lineage in the affected population may unmask the 
presence of a functional variant on the Y, in linkage with the neutral 
mutation defining the haplogroup. The analysis of three different 
ethnic groups, a total of 229 cancer patients versus 276 ethnically 
and geographically matched controls showed lack of association 
Figure 1. Schematic representation of the Y chromosome showing (A) the deletion intervals AZFa, AZFb 
and AZFc regions. AZFb deletions overlap with the AZFc region. Yp: short arm of the Y chromosome, 
cen: centromere, Yq: long arm of the Y chromosome, PAR: pseudoautosomal region. (B) the AZFc region 
with the indication of the location of multicopy genes and transcription units in the reference sequence 
published by Skaletsky et al., (2003). This region contains a number of repeated sequences with the same 
orientation (matching arrows) which through intrachromosomal recombination may lead to deletions. (C) 
gr/gr deletions which remove half of the AZFc gene content, but can vary in breakpoints. This deletion 
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may, in theory, decrease the risk.49 Given that the length of the poly-
morphic polyglutamin stretch (encoded by CAG repeats) influences 
the transactivation capacity of the receptor, variations in its length, 
still in the polymorphic range, may confer stronger or weaker andro-
geneicity. Studies which focused on TGCT patients failed to find 
an association between CAG repeat length and cancer risk.50-52 The 
observation by one single group about an association between long 
CAG tracts and tumor progression to nonseminomas and a clinically 
more aggressive disease awaits confirmation.51
A role in genetic susceptibility to endocrine disruption can be 
hypothesized for polymorphisms in those genes involved in pathways 
related to the action and metabolism/detoxification of endocrine 
disrupters or endogenous estrogens. According to the intrauterine 
origin of TGCTs a logical target for susceptibility factors is repre-
sented by maternal genetic polymorphisms. A recent case-parent 
study investigated a number of genes involved in the oestrogen 
metabolism and found an association between cytochrome P450 
gene polymorphisms (both maternal and in the index subjects) and 
increased risk of TGCTs.53 Given the small sample size, this highly 
promising finding needs to be replicated by independent studies.
The Role of Somatic Genetic Changes
Chromosomal constitution. Many studies investigated the chro-
mosomal constitution of TGCTs, including its precursor lesion 
CIS.1,6 Besides a consistent aneuploidy, specific chromosomal gains 
and losses are identified, but the only recurrent structural imbal-
ance is the gain of the short arm of chromosome 12, mostly as 
isochromosomes. The majority of studies indicate that gain of 12p 
is progression related. In spite of various attempts, there is no single 
12p-target gene identified. A number of genes have been suggested to 
be relevant, including KRAS2, NANOG, although the actual proof 
is lacking so far.
Single nucleotide polymorphism analysis in TGCTs demonstrated 
the presence of so called uniparental disomies, especiallly in nonsemi-
noma.54 Although of putative interest, the biological relevance 
remains to be shown.
Currently a number of integrated analyses of expression of genes 
and proteins as well as DNA copy changes are performed.1,6,55,56 
Overall, the data suggest a close correlation between the two, in which 
the expression drives the chromosomal imbalances or vice versa.
Mutational status. Various studies with the goal to identify 
pathogenetic mutations have been performed on TGCTs. Although 
mutations have been identified, these seem to be limited in 
frequency, with the possible exceptions of c-KIT and KRAS-2, and 
more recently BRAF. c-KIT is a kinase receptor relevant for a number 
of crucial processes during normal development, including survival 
and migration of PGCs from the epiblast to the genital ridge.57-59 
In normal development of germ cells, c-KIT is downregulated upon 
arrival of the PGCs in the genital ridge,57,58 although it can still be 
detected at a relatively low level in human spermatogonia.60 c-KIT is 
also present at a high level in CIS and gonadoblastoma and is overall 
downregulated upon invasive growth. Activating mutations, leading 
to a stem cell factor (SCF) independent active receptor, have been 
found predominantly in bilateral TGCTs but some studies found 
them mainly in primary unilateral seminomas.1,6 The sensitivity of 
the mutation detection may be responsible for the conflicting data, 
as well as tumor progression-related loss. That indeed c-KIT has 
between Y haplogroups and TGCTs.36-38 Similarly, classical AZF 
deletions (removing all STSs located in a given AZF region) are not 
associated with TGCT and were not found at all in a total of 575 
cancer patients.37,39-41 Single STS deletions on the Y chromosome are 
likely to be due to PCR artefacts or to polymorphisms in the primer 
sequence binding site41,42 which implies that they must be confirmed 
by sequencing the deletion breakpoints. Since confirmed single STS 
deletions have not been described in the literature the appealing link 
between Y chromosome instability (expressed as mosaic or single STS 
deletions) and TGCT remains to be established.
On the contrary of classical AZF deletions, “gr/gr” deletion has 
been reported as a significant risk factor for TGCT. A two fold 
increased risk of TGCT for “gr/gr” deletion carriers in 1807 affected 
subjects has been observed with an even higher—three fold—increase 
in familial cases.43 In contrast to what would be expected, the authors 
found that probands from TGCT families exhibiting maternal lineage 
were at greater risk than those exhibiting paternal lineage. The asso-
ciation between “gr/gr” deletion and TGCT was not confirmed in a 
separate UK study42 and an Italian study.37 In general, the analysis of 
a very large group of subjects might be more appropriate for detecting 
genetic predispositions acting at low penetrance than smaller studies, 
however the situation is more complex for the Y chromosome than 
for the rest of the genome because of potential biases such as popula-
tion stratification.44 Ethnic and geographic matching of cases and 
controls is fundamental when searching for Y related factors and 
the multicenter study,43 although very large, contained only 15% 
of cases and 23% of unaffected males from designed epidemiologic 
case-control studies. Moreover, since both gr/gr deletions and familial 
cases are rare the strength of the large multicenter study is still limited 
and would require further confirmation.
The above discussed data indicate an unlikely role for AZF dele-
tions and genes or gene families in TGCT formation. However 
assuming that only a subgroup of patients will have a Y related 
etiology, the most likely candidates are those who present both 
impaired spermatogenesis and a TGCT. Only a small proportion of 
published studies were able to collect data on semen analysis, there-
fore, final conclusions are awaited.
An interesting candidate to explain the role of the Y chromo-
some in the development of TGCTs is the Testis Specific Protein on 
the Y chromosome (TSPY). This multicopy gene lies within the so 
called Gonadoblastoma on the Y chromosome (GBY) region, related 
to malignant transformation of primordial germ cell/gonocytes in 
patients with specific forms of DSD, especially hypovirilization and 
gonadal dysgenesis, and is highly expressed in CIS and GB.28,45,46 
Although the mechanism is still unknown, it might be related to cell 
cycle control.47
Other Polymorphisms
Only a few association studies are available in the literature.6,48 
The two polymorphic microsatellites of the androgen receptor 
(AR) gene (CAG and GGN repeats in exon 1) have been studied 
in relationship with infertility,35 cryptorchidism as well as TGCTs. 
The rational for the analysis of AR polymorphisms derives from a 
proposed—not yet elucidated—role for androgen function in early 
foetal testicular development. While androgen insensitivity is an 
important risk factor for TGCTs, especially demonstrated in patients 
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TGCTs than can be explained by either local tumor or general cancer 
effect, it is likely that mutations in spermatogenic candidate genes will 
be involved only in those patients who are associated with reduced 
sperm count. Up to now no specific screening for mutations in sper-
matogenesis candidate genes has been performed in large enough 
group of selected cases with impaired spermatogenesis. An other even 
more promising alternative is a genome wide association study which 
could provide susceptibility locus mapping even for low penetrance 
disease loci. In the era of International Hapmap project (2003) and of 
appropriate technology platforms such studies became now a realistic 
way to approach multifactorial diseases. In addition, introduction 
of (high throughput) mutation and genome imbalance analyses and 
expression profiling has advanced our understanding of the pathoge-
netic mechanisms involved in TGCTs. However, this has just began 
to unravel the complex interaction of multiple pathways involved, for 
which an integrated approach would be most informative.
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an important role in the pathogenesis of TGCTs, is supported by 
the observation that this gene can be overexpressed due to a highly 
restricted genomic amplification only including this gene.61 The 
most recent identification of SCF being a diagnostic marker for 
early malignant germ cells is of interest in this context.28 The c-KIT 
signaling pathway has been linked to PI3K,
62 both in mouse PGCs as 
well as TGCTs. It is of interest that activating KRAS2 mutations are 
found in TGCTs.63,64 Activation of a mutated KRAS2 results in an 
increased in vitro survival of seminoma cells,64,65 which are normally 
not able to survive outside the patient, as well as an earlier age at 
clinical presentation of the tumor.
The proto-oncogene BRAF has been shown to be mutated in a 
variety of cancers, including TGCTs.66 The affected pathway is the 
MEK-pathway, in which RAS also act. Activating mutations of KRAS 
and BRAF are mutually exclusive in TGCTs. A correlation between 
BRAF mutation and hypermethylation of the promoter of hMLH1 
has been reported.67 Since hMLH1 is involved in mismatch repair, 
absence or mutations in this gene results in micro satellite instability 
(MSI). Indeed, MSI instability has been reported to be related to 
treatment resistance (i.p. cisplatin-based) in multiple studies.68-71 
However, the exact link between BRAF status, MSI and treatment 
sensitivity of TGCTs has to be clarified.
An overall low mutation frequency is rather exceptional for solid 
cancers, although it seems is the rule for TGCTs. That this is indeed 
not due to the pre-selection of genes under investigation, but an overall 
phenomenon is supported by the results of a high throughput investi-
gation on the mutation status of the genome.72,73 This might again be 
related to the embryonic origin of the tumors. In fact, embryonic stem 
cells have a unique mechanism is which one of the two DNA strands 
is kept protected against any form of mutations.74 This protects the 
DNA from anomalies to be transmitted to the next generation.
TP53 and microRNAs. One of the intriguing observations is 
that also TP53 is hardly mutated in TGCTs for.1,6 It is however, 
interesting that TP53 target genes have been found to be frequently 
hypermethylated in TGCTs.75 The explanation for the wild type 
TP53 status in TGCTs was obtained, amongst others, as a result of 
the expression analysis of certain microRNAs.76 The miRNA cluster 
371–373 (mapped to chromosome 19) is specifically expressed in the 
seminomas and embryonal carcinomas and as expected in human 
embryonic stem cells.77 This cluster of microRNAs was before found 
to be able to mimick the presence of a mutated TP53 in overruling 
cellular senescence in a high throughput in vitro model system.78 The 
miRNAs interact with the 3' UTR of the mRNA encoding the tumor 
suppressor gene protein LATS-2, which is involved in the regulation 
of G1-S transition in the cell cycle. LATS-2 is indeed a downstream 
target of TP53, and inactivation of TP53 results in absence of 
LATS-2 protein, and thereby overruling cellular senescence.
Conclusions
The analysis of familial cases did not provide evidence for linkage 
to any locus possibly because there are several moderate-risk genes 
involved in development of TGCTs. This implies that alternative 
approaches-not based on linkage analysis-should be taken into consid-
eration for future investigations. One option could be the analysis of an 
enriched study population in specific subgroups (for example TGCT 
patients with impairment of spermatogenesis) versus unaffected 
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